Corvus Pharmaceuticals (CRVS) Operating Expenses (2015 - 2026)

Corvus Pharmaceuticals' Operating Expenses history runs 12 years deep, the most recent figure standing at $14.9 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 49.94% year-over-year to $14.9 million in Q1 2026; TTM through Mar 2026 was $35.7 million, a 54.5% increase from a year earlier, with the FY2023 full-year figure at $23.4 million, down 28.12% from the prior year.
• Operating Expenses rose to $14.9 million in Q1 2026 per CRVS's latest filing, from $10.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $14.9 million in Q1 2026 and bottomed at $5.6 million in Q3 2023.
• The 5-year median for Operating Expenses is $7.0 million (2022), against an average of $8.1 million.
• Across the five-year window, Operating Expenses tumbled 55.42% in 2023 and surged 72.87% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $5.7 million in 2022, then retreated by 0.26% to $5.7 million in 2023, then gained by 28.38% to $7.3 million in 2024, then surged by 45.72% to $10.6 million in 2025, then surged by 40.72% to $14.9 million in 2026.
• Per Business Quant, the three latest CRVS Operating Expenses figures stand at $14.9 million (Q1 2026), $10.6 million (Q3 2025), and $10.3 million (Q2 2025).